TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3871883
Drug: Propranolol 5
Normalized name: propranolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 5 mg every 6 hours orally (n = 82)
Study: 30416083
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg Q4W
Study: 30661249
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg Q8W
Study: 15292326
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy for 6 months
Study: 11573752
Drug: Medical Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutrition Therapy (MNT) from dietitians using a NCEP based lowering protocol
Study: 9758087
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (cand.cil.) 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Study: 9758087
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (cand.cil.) 8-16 mg o.i.d. for 12 weeks
Study: 7522510
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) based chemotherapy or chemoimmunotherapy
Study: 2978286
Drug: 0.9% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% (w/v) NaCl solution (saline)
Study: 23208945
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise
Study: 27998002
Drug: rBet v
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rBet v 1-FV allergen immunotherapy (AIT)
Study: 26852502
Drug: Local ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ozone therapy
Study: 26852502
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of local and general ozone therapy
Study: 26852502
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy alone
Study: 12952263
Drug: Lyso-PAF (L-PAF)
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyso-PAF (L-PAF)
Study: 10649811
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE), 1.25 mg/d
Study: 10649811
Drug: Esterified estrogens,
Normalized name: Esterified Estrogens, 1.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens, 0.625 mg + methyltestosterone, 1.25 mg/d
Study: 10649811
Drug: Esterified estrogens,
Normalized name: Esterified Estrogens, 1.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens, 1.25 mg + methyltestosterone, 2.5 mg/d
Study: 1986661
Drug: Flumazenil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (up to 1 mg)
Study: 25040613
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 50 mcg once-daily
Study: 25040613
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 mcg twice-daily
Study: 18192544
Drug: Salbutamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol plus AIR insulin (moderate asthma group only)
Study: 8611060
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment combined with weekly relapse prevention psychotherapy
Study: 1934862
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg) with 300 ml water
Study: 7073026
Drug: Isoetharine (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoetharine (1% solution)
Study: 7073026
Drug: Isoproterenol (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (0.5% solution)
Study: 6734291
Drug: Dual screen
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual screen with annual chest x-ray examination and four monthly sputum cytology evaluation
Study: 27484701
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP adjusted group)
Study: 27484701
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP unadjusted group)
Study: 25522403
Drug: Silexan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan (160 mg daily for a minimum of 8 weeks)
Study: 22460728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (never used antacid medications)
Study: 20394460
Drug: Pharmacist management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist management of diabetes (including medication management, patient education, and disease control)
Study: 17498718
Drug: Ethanol-water solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol-water solution
Study: 8739175
Drug: Braun/Oral-B Plak
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun/Oral-B Plak Control (D7)
Study: 1756202
Drug: m-CPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (0.5 mg/kg)
Study: 21704493
Drug: Caffeine (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (480 mg)
Study: 1337607
Drug: Baclofen 5
Normalized name: baclofen 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 5 mg
Study: 1337607
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg
Study: 7042732
Drug: Baclofen 20
Normalized name: baclofen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 20 mg
Study: 28193257
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day to a maximum of 50 mg/day for 10 days
Study: 22027927
Drug: ATG/Dac (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG/Dac (3 ATG, 2 Dac doses)
Study: 22027927
Drug: ATG/alemtuzumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG/alemtuzumab (1 dose each)
Study: 16827637
Drug: Azithromycin-containing toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin-containing toothpaste (85 mg azithromycin per gram, prescribed b.i.d., 1.5 cm for 1 month)
Study: 15018588
Drug: Cetrorelix (0.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (0.25mg daily injections or 3mg intermediate depot preparation)
Study: 15018588
Drug: Ganirelix (0.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (0.25mg daily injections)
Study: 15018588
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist multiple-dose protocol
Study: 15018588
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist single-dose protocol
Study: 15018588
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist cycles
Study: 11371127
Drug: GnRH analogs
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analogs (leuprolide acetate) administered prior to and during polychemotherapy (PCT)
Study: 8192646
Drug: Composite index
Normalized name: DRESSING,COMPOSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite index for treatment outcome research with social phobia
Study: 28053275
Drug: CRP (C-reactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP (C-reactive protein) increase (per 10 mg/l)
Study: 28053275
Drug: Baseline creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline creatinine increase (per 100 µmol/l)
Study: 21854503
Drug: SBR759 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759 (3.0 or 4.5 g/day)
Study: 21854503
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (2.4 or 4.8 g/day)
Study: 17971091
Drug: peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon α‐2a (40KD) 180μg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Study: 16947384
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg by weight range)
Study: 16947384
Drug: Abatacept plus
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept plus biologic agent
Study: 16947384
Drug: Other subgroups
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other subgroups (not receiving biologic agent)
Study: 12969096
Drug: Methohexital plus
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital plus remifentanil (0.625 mg kg‐1 methohexital + 1 micro g kg‐1 remifentanil)
Study: 12969096
Drug: Methohexital alone
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital alone (1.25 mg kg‐1)
Study: 11885182
Drug: Non-HA-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HA-coated implants
Study: 11885170
Drug: Implants mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants mobile at uncovering
Study: 11885170
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with facial bone thickness >= 1.8 mm
Study: 11885170
Drug: Implants that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants that failed to integrate
Study: 11885170
Drug: HA-coated vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated vs non-HA-coated implants
Study: 9383226
Drug: Immediate administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate administration of G-CSF (day +1)
Study: 9383226
Drug: Delayed, patient-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed, patient-dependent G-CSF therapy (first day when ANC was below 0.5 x 10[9]/1)
Study: 8463731
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone phosphate 1.0% administered 4 times daily to the right eye
Study: 8463731
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to the left eye
Study: 8463731
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone phosphate 1.0%
Study: 3534869
Drug: Captopril once
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril once daily (100 mg)
Study: 3534869
Drug: Captopril twice
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril twice daily (50 mg)
Study: 22132827
Drug: Amoxicillin trihydrate-potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin trihydrate-potassium clavulanate (Clavamox)
Study: 20940176
Drug: Maternal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal plasma levels of PFOS (ng/mL)
Study: 20940176
Drug: Maternal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal plasma levels of PFOA (ng/mL)
Study: 18723709
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg, max 10 mg over 5 min)
Study: 8934257
Drug: Cyclical treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical treatment with 2 mg of oral estradiol valerate in combination with 250 micrograms of levonorgestrel for the last ten days (Cyclo Progynova)
Study: 8934257
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 2 mg estradiol valerate orally in combination with a 20 micrograms per 24 hour levonorgestrel releasing intrauterine device
Study: 8320744
Drug: DDATHF 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDATHF 3.0 mg/m2 per week
Study: 8320744
Drug: DDATHF 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDATHF 4.5 mg/m2 per week
Study: 8320744
Drug: DDATHF 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDATHF 6.0 mg/m2 per week
Study: 2883003
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Epanolol-Visacor (ISA)
Study: 2883003
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Metoprolol (without ISA)
Study: 27363578
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy (GV14 and acupuncture at EX-HN3, ST2, LI20, EX-HN8, GV23, LU7, LU5, LI4) three times a week for 4 weeks
Study: 27363578
Drug: Oral loratadine
Normalized name: loratadine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loratadine 10 mg/day for 4 weeks
Study: 24032192
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy
Study: 18511016
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral estradiol (oE(2))
Study: 18511016
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg transdermal estradiol (tE(2))
Study: 8757574
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion
Study: 20368558
Drug: IFN‐alpha monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha monotherapy
Study: 12767369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery and immunotherapy
Study: 12767369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFN‐alpha and Il‐2
Study: 12767369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFN‐alpha, Il‐2 and 5‐fluorouracil (5‐FU)
Study: 10493320
Drug: Flunisolide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (1000 microg twice daily)
Study: 10493320
Drug: Budesonide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1000 microg twice daily)
Study: 10493320
Drug: Beclomethasone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (1000 microg twice daily)
Study: 10493320
Drug: Triamcinolone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (1000 microg twice daily)
Study: 10493320
Drug: Fluticasone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (1000 microg twice daily)
Study: 972558
Drug: Drug profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug profile provided to half of the study population for a full year.
Study: 972558
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug profile provided (control group).
Study: 21464262
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) for 20 minutes
Study: 9024260
Drug: GHRH infusion
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Study: 9024260
Drug: GHRP-2 infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GHRP-2 infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Study: 9024260
Drug: GHRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH plus GHRP-2 infusion
Study: 7898866
Drug: Early-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-treatment group (5-FU injections started 2.4 +/- 0.6 days postoperatively)
Study: 7898866
Drug: Delayed-treatment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment group (5-FU injections started 12.6 +/- 5.4 days postoperatively)
Study: 7898866
Drug: Early-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-treatment group
Study: 7898866
Drug: Delayed-treatment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment group
Study: 30064491
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg then 40 mg 2 weeks later)
Study: 25952495
Drug: Medication-taking consistency
Normalized name: Fusion protein consisting of il-15n72d and il-15rasu/fc
DrugBank: Nogapendekin alfa (DB18740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-taking consistency
Study: 14614165
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CTLA4Ig per kilogram
Study: 14614165
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg CTLA4Ig per kilogram
Study: 11374857
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin
Study: 11374857
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (Niaspan)
Study: 1385567
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg intravenous doses, two doses: one before anesthesia induction and one 8 hours later)
Study: 1385567
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two doses of placebo vehicle: one before anesthesia induction and one 8 hours later)
Study: 31591063
Drug: Ramucirumab plus
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab plus erlotinib (150 mg/day erlotinib, 10 mg/kg ramucirumab every 2 weeks)
Study: 31591063
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus erlotinib (150 mg/day erlotinib)
Study: 21451504
Drug: PF‐4878691 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐4878691 (3, 6, and 9 mg doses, twice a week for 2 weeks)
Study: 21451504
Drug: PF‐4878691 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐4878691 (9 mg dose)
Study: 19653753
Drug: Body-related objects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body-related objects (e.g., cup) with movement toward the subject's body
Study: 19653753
Drug: World-related objects
Approvals — FDA: no, EMA: no, PMDA: no
Description: World-related objects (e.g., pincers) with movement in the opposite direction
Study: 16965983
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin, 4000 IU/d, n = 56 hypertensive patients)
Study: 16965983
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 38 hypertensive women)
Study: 14976884
Drug: Modified Zhizhu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Zhizhu pill (ZZP) 100 ml, twice daily, orally taken half an hour before meal
Study: 14976884
Drug: Ranitidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 0.15 g, twice daily and Cisapride 10 mg, three times a day, orally taken before meal
Study: 9382344
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (Group 2)
Study: 27118284
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 3)
Study: 8407393
Drug: IUdR 96
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUdR 96 hr infusion schedule
Study: 8407393
Drug: IUdR 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUdR 48 hr infusion schedule
Study: 8407393
Drug: IUdR 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUdR 24 hr infusion schedule
Study: 22092641
Drug: Moraxella bovis
Normalized name: Moraxella catarrhalis subsp. catarrhalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moraxella bovis autogenous vaccine
Study: 8290859
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg daily for 28 days)
Study: 20444662
Drug: glimepiride+metformin
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride+metformin
Study: 18721198
Drug: Single gram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single gram of intramuscular ceftriaxone
Study: 18721198
Drug: 3-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day course of oral ciprofloxacin
Study: 18721198
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 500 mg of ciprofloxacin
Study: 17013573
Drug: TAX/RT (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAX/RT (paclitaxel 90 mg/m² or docetaxel 35 mg/m²)
Study: 17013573
Drug: TAX/CIS/RT (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAX/CIS/RT (paclitaxel 135 mg/m² d1 and cisplatin 20 mg/m² d1-5 q28)
Study: 15226460
Drug: NCEP Step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NCEP Step 2 high‐fish diet (n = 11, 26% of energy as fat, 4.5% as saturated fat, and 15 mg cholesterol/MJ)
Study: 15226460
Drug: NCEP Step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NCEP Step 2 low‐fish diet (n = 11, 26% of energy as fat, 4.0% as saturated fat, and 11 mg cholesterol/MJ)
Study: 14685384
Drug: High-fat oral
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat oral supplement (Group I)
Study: 14685384
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet without supplement (Control Group II)